

MOL # 29769

Title Page:

Native rat hippocampal 5-HT_{1A} receptors show constitutive activity.

Jean-Claude Martel, Anne-Marie Ormière, Nathalie Leduc,
Marie-Bernadette Assié, Didier Cussac and Adrian Newman-Tancredi

Departments of Neurobiology 2 (JCM, AMO, NL, MBA,ANT) and Molecular and Cellular
Biology (DC), Institut de Recherche Pierre Fabre, Castres, France

MOL # 29769

Running Title Page:

a) Running title:

Constitutive activity of native rat 5-HT_{1A} receptors.

b) Corresponding author:

Jean-Claude MARTEL
Division de Neurobiologie 2
Centre de Recherche Pierre Fabre
17 Avenue Jean Moulin
81106 Castres cedex, France
Tel : 33(0)563714288
Fax : 33(0)563714299
Email : jean.claude.martel@pierre-fabre.com

c) Article Statistics

Text pages :	23
Tables:	2
Figures:	2
References:	40
Abstract:	234 words
Introduction:	566 words
Discussion:	1500 words

d) Abbreviations

(+)8-OH-DPAT: (+)8-hydroxy-2-(di-n-propylamino)tetralin; 5-HT: 5-hydroxytryptamine; CHO: Chinese hamster ovary; EDTA: ethylene dinitril-O-tetraacetate; DPM: disintegration per minute; DTT: dithiothreitol; G α_x : x subunit of heterotrimeric G-alpha protein; GPCR: G-protein-coupled receptor; GDP: guanosine diphosphate; GTP: guanosine triphosphate; HEK: Human embryonic kidney; SPA: scintillation proximity assay; [³⁵S]GTP γ S: guanosine-5'-O-(3-[³⁵S]thio)-triphosphate; Sf9: *Spodoptera frugiperda*.

MOL # 29769

Abstract:

Previous studies have shown that human 5-HT_{1A} receptors stably expressed in transfected cell lines show constitutive G-protein activity, as revealed by the inhibitory effect of inverse agonists, such as spiperone, on basal [³⁵S]GTPγS binding. In the present study, we evaluated the constitutive activity of native rat 5-HT_{1A} receptors in hippocampal membranes. Using anti-Gα_o-antibody capture coupled to scintillation proximity assay under low sodium (30 mM) conditions, we observed high basal [³⁵S]GTPγS binding to Gα_o subunits (defined as 100%). In these conditions, 5-HT and the prototypic selective 5-HT_{1A} agonist (+)-8-OH-DPAT, both stimulated [³⁵S]GTPγS binding to Gα_o to a similar extent, raising binding to approximately 130% of basal with pEC₅₀ values of 7.91 and 7.87, respectively. The 5-HT_{1A}-selective neutral antagonist WAY100,635 could block these effects in a competitive manner with pK_b values (5-HT: 9.57; (+)-8-OH-DPAT: 9.52) that are consistent with its pK_i value at r5-HT_{1A} receptors (9.33). In this native receptor system, spiperone and methiothepin reduced basal [³⁵S]GTPγS binding to Gα_o in a concentration-dependent manner to 90% of basal with pIC₅₀ of 7.37 and 7.98, respectively. The inhibition of basal [³⁵S]GTPγS binding induced by maximally effective concentrations of spiperone (10 μM) or methiothepin (1 μM) was antagonised by WAY100,635 in a concentration-dependent manner (pK_b: 9.52 and 8.87, respectively), thus indicating that this inverse agonism was mediated by 5-HT_{1A} receptors. These data provide the first demonstration that native rat serotonin 5-HT_{1A} receptors can exhibit constitutive activity in vitro.

MOL # 29769

Introduction:

Constitutive activity of G-protein-coupled receptors (GPCR) provides a mechanistic basis for inverse agonism, a phenomenon observed in heterologous expression systems where some pharmacological agents are able to inhibit basal activity, as measured in second messenger system assays (de Ligt *et al.*, 2000; Kenakin, 2004). This phenomenon has been described for several GPCR, and a number of clinically relevant drugs have been shown to act as inverse agonists on some GPCR (Milligan, 2003a; Kenakin, 2004). Constitutive activity has been described in a number of recombinant systems and in “physiological” peripheral tissue preparations (de Ligt *et al.*, 2000), but only rarely in native brain tissue, the few exceptions being serotonin 5-HT_{2C} receptors (De Deurwaerdere *et al.*, 2004) and H₃ histaminergic receptors (Morisset *et al.*, 2000). Moreover, there are evidences that mutated GPCR with elevated constitutive activity are associated with some human diseases (Kenakin, 2004; de Ligt *et al.*, 2000; Seifert and Wenzel-Seifert, 2002). A better characterization of this phenomenon may thus improve our understanding of the mechanisms of action of clinically important drugs, and may also help improve future drug development.

Serotonin 5-HT_{1A} receptors, which are members of the GPCR family, are key targets for the treatment of mood disorders including anxiety and depression (Barnes and Sharp, 1999), and may also improve the outcome of psychotic disorders (Meltzer *et al.*, 2003; Millan, 2000; Newman-Tancredi *et al.*, 2005). Several reports have shown that human (h)5-HT_{1A} receptors expressed in stably transfected cell lines showed constitutive activity as revealed by the inverse agonist properties of spiperone and methiothepin in that heterologous expression system (Newman-Tancredi *et al.*, 1997a; Newman-Tancredi *et al.*, 1997b; Stanton and Beer, 1997; McLoughlin and Strange, 2000). The effects of spiperone were concentration-dependent and could be blocked by the selective neutral 5-HT_{1A} receptor

MOL # 29769

antagonist WAY100,635. Similarly, h5-HT_{1A} receptors constitutive activity could be demonstrated on a specific coupling to GTP-binding protein G_z when this particular G-protein was co-expressed with h5-HT_{1A} receptor in *Spodoptera frugiperda* (Sf9) cell line (Barr and Manning, 1997), and on G α_{i3} activation in *Chinese hamster ovary* (CHO) cells expressing h5-HT_{1A} receptors (Newman-Tancredi *et al.*, 2002). Constitutive activity of 5-HT_{1A} receptors could also be demonstrated when the receptor was coupled to G α_{i1} in HEK cells using a fusion protein paradigm (Milligan *et al.*, 2001). In light of these observations, several groups have evaluated constitutive activity of 5-HT_{1A} receptors in brain tissue environment (Alper and Nelson, 1998; Odagaki and Fuxe, 1995; Newman-Tancredi *et al.*, 2003b; Odagaki and Toyoshima, 2005a; Odagaki and Toyoshima, 2005b). However, constitutive activity of native 5-HT_{1A} receptors has not been described to date.

Recent advances in [³⁵S]GTP γ S binding assays have improved the selectivity of this technique for studying GPCR (Milligan, 2003b). Scintillation proximity assay (SPA) can be coupled with G-alpha selective antibodies in [³⁵S]GTP γ S binding assays, allowing detection of the response of a single G α -protein subtype to pharmacological manipulation within an homogenate (Newman-Tancredi, 2003; Wu and Liu, 2005). The rat hippocampus contains high densities of 5-HT_{1A} receptors (Barnes and Sharp, 1999) that may be essentially coupled to G α_o (Mannoury la Cour *et al.*, 2006). In the present study, we characterized the effect of selected 5-HT_{1A} receptor drugs on a SPA-based G α_o -selective immunocapture assay using two agonists (serotonin and (+)-8-OH-DPAT) and two inverse agonists (spiperone and methiothepin). These results indicate that 5-HT_{1A} receptors constitutively activate G α_o subunits in rat brain tissue homogenate. Part of this work has been presented in an abstract form (Martel *et al.*, 2005).

MOL # 29769

Materials and methods:

Animals were handled and cared for in accordance with the Guide for the Care and Use of Laboratory Animals (ILAR, NRC, USA, 1996) and the European Directive EEC/86/609, and the protocol (N° 001) was carried out in compliance with French regulations and with local Ethics Committee Guidelines for animal research .

Receptor affinities in rat hippocampal membranes:

Frozen hippocampi of male rats [Ico: OFA SD (I.O.P.S. Caw); Iffa Credo, France] weighing 240-260 g were used for binding studies and were stored at -80° C prior to use. The membrane preparations and binding assays were performed in duplicate as described previously (Assie *et al.*, 1999). Briefly, membranes were homogenized in 20 volumes of cold Tris-HCl buffer (50 mM, pH 7.4 at 25° C), washed with 2 cycles of centrifugation/resuspension, followed by a 10 minute incubation at 37°C which ended with a final cycle of centrifugation/resuspension. Membranes (750 µg tissue/well) were incubated at 23°C in 96 deep well microplates containing 1 nM [³H]8-OH-DPAT, and increasing concentrations of drugs ranging from 10⁻¹¹M to 10⁻⁵M. Following a 2 hour incubation period, the microplate contents were rapidly filtered under vacuum through GF/B unifilter microplates with two rapid 2 ml washes with ice-cold Tris-HCl buffer. Non specific binding was defined with 10 µM 5-HT while total binding was defined in the absence of any displacer. The radioactivity retained on the filters was measured by scintillation spectroscopy (TopCount, PerkinElmer) in 40 µl of scintillation fluid (Microscint 20, PerkinElmer). The results of displacement experiments were analysed using the non-linear regression program PRISM v 4.03 (GraphPad software) which allowed calculation of an IC₅₀. K_i were calculated using the Cheng-Prusoff equation (Cheng and Prusoff, 1973): $K_i = IC_{50} / (1 - ([Ligand] / K_D Ligand))$ where [Ligand] is the measured concentration of [³H](+)-8-OH-DPAT in the assay and K_DLigand is the affinity of [³H](+)-8-OH-DPAT in that assay (0.75 ± 0.08 nM). Density of 5-HT_{1A} receptors in that assay was 14.3 ± 0.8 fmol/mg fresh tissue (corresponding to approximately 300 fmol/mg proteins).

MOL # 29769

Scintillation Proximity Assay (SPA):

Hippocampi from male rats [Ico: OFA SD (I.O.P.S. Caw); Iffa Credo, France] weighing 240-260 g were dissected on a cold plate and frozen at -80°C until used. Tissues were homogenized in cold HEPES-DTT buffer (20 mM HEPES pH 7.0, 0.2 mM EDTA, 0.2 mM DTT) with 1 mM GTP using a polytron, GTP favouring endogeneous ligand dissociation. The homogenate was incubated at 35°C for 15 minutes to favour endogenous ligand dissociation. Membranes were washed by 2 cycles of centrifugation at 20 000 X g for 15 minutes at 4°C and resuspension in cold HEPES-DTT with 1 mM GDP. Final pellet was resuspended in 300 volumes (based on tissue weight) HEPES-DTT buffer containing 5 mM MgCl_2 , 100 mM (Galpha-selective antibodies assay) or 30 mM (pharmacological assay) NaCl and 50 μM GDP (HEPES-DTT assay buffer).

All reactions were performed at room temperature on 96 well plates in a final volume of 200 μl HEPES-DTT assay buffer. Membranes (8 μg protein/well) were pre-incubated for 30 minutes at room temperature with drugs (agonist +/- antagonist), buffer (to define basal) or 10 μM $\text{GTP}\gamma\text{S}$ (to define non-specific). At the end of this pre-incubation, 0.4 nM [^{35}S]GTP γS was added and the membranes were incubated for 60 minutes. Incubation was stopped by adding Nonidet NP-40 and the plate was agitated for another 30 minutes before addition of 0.2 μg anti-G α -selective antibodies to each well. The antibodies used were rabbit polyclonal anti-G $\alpha_{q/11}$, anti-G α_{i3} and anti-G $\alpha_{s/olf}$ from Santa Cruz Biotechnology (Santa Cruz, CA), or mouse monoclonal anti-G α_o and anti-G α_{i1} from Biomol (Plymouth Meeting, PA).

Anti-G $\alpha_{q/11}$, anti-G α_{i1} and anti-G $\alpha_{s/olf}$ have been characterized previously by western blot using purified recombinant G α_{i1} , G α_{i2} , G α_{i3} , G α_o , G $\alpha_{q/11}$ and G $\alpha_{s/olf}$ protein subtypes (Cussac *et al.*, 2002; Cussac *et al.*, 2004), and are highly selective for their respective G-protein subtypes. As described by the manufacturer, we observed crossreactivity of anti-G α_{i3} with G α_{i1} and G α_{i2} , with a stronger reaction on G α_{i3} (data not shown). Specificity of anti-G α_o was

MOL # 29769

assessed by western blot using 50 ng of purified recombinant $G\alpha_{i1}$, $G\alpha_{i2}$, $G\alpha_{i3}$, $G\alpha_o$, $G\alpha_{q/11}$ and $G\alpha_{s/olf}$ protein subtypes as described previously (Cussac *et al.*, 2002; Cussac *et al.*, 2004). Anti- $G\alpha_o$ are highly selective for $G\alpha_o$ (Figure 1A). Note that the basal signal for each antibodies will depend both on the affinity and selectivity of these antibodies for the G-protein subtype(s), and the revelation system (affinity of secondary antibodies) and cannot therefore be compared. The primary antibodies were left to react for 60 minutes under agitation before adding 50 μ l of the secondary antibodies (anti-rabbit or anti-mouse coupled to scintillation proximity assay beads, Amersham), diluted according to manufacturer's recommendations. The secondary antibodies were left to react for another 60 minutes and the plate was centrifuged at 1 000 X g for 15 minutes at room temperature to take the complex down at the bottom of the well and radioactivity was immediately measured on a top-count radioactivity counter (Perkin-Elmer). Raw DPM data were transformed by subtracting non-specific and normalizing to % of basal [35 S]GTP γ S binding. All pharmacological parameters were derived from sigmoid non-linear regression using Graphpad Prism version 4.03. For antagonism by WAY100,635, pKb were calculated using the Cheng-Prusoff equation ($Kb=IC_{50}/(1-([Ago]/EC_{50Ago}))$) where [Ago] is the fixed concentration of agonist used for the antagonism assay, and EC_{50Ago} is the EC_{50} of that agonist when tested alone.

MOL # 29769

Results:

The G α protein subtypes activated by 5-HT_{1A} in rat hippocampus were evaluated using SPA-based antibody capture assay with a set of antibodies selective for different G α -proteins (see materials and methods for details). Table 1 lists the basal [³⁵S]GTP γ S binding (in DPM) observed with the various antibodies, and the absolute (DPM) and relative (% BASAL) changes elicited by 10 μ M (+)8-OH-DPAT. The maximal basal [³⁵S]GTP γ S binding was observed with the anti-G α_o -selective antibodies (Figure 1A), and these antibodies also showed the maximal absolute (+4607 DPM) and relative (+71%) increases following (+)8-OH-DPAT treatment (Table 1). A moderate (+46%) increase in relative [³⁵S]GTP γ S binding was also observed with anti-G α_{i3} antibodies (Table 1) but absolute [³⁵S]GTP γ S binding represented only a minor fraction (+371 DPM, or 8% of the response observed with G α_o on a DPM basis; Table 1). Due to the cross reactivity of anti-G α_{i3} antibodies with G α_{i1} and G α_{i2} , this increase may be predominantly due to G α_{i2} and/or G α_{i3} proteins as no change of [³⁵S]GTP γ S binding was seen with G α_{i1} -selective antibodies (Table 1), thus demonstrating that 5-HT_{1A} receptors do not couple to G α_{i1} in rat hippocampus. We therefore used the G α_o -selective antibodies for investigating constitutive activity of 5-HT_{1A} receptors in rat hippocampal membrane preparations.

Low sodium concentrations (30 mM) and relatively high GDP concentrations (50 μ M) were used to detect 5-HT_{1A} receptors constitutive activity in this system. Under those conditions, basal [³⁵S]GTP γ S labelling of G α_o was about 25 000 DPM, and this basal value was defined as 100% (figures 1 and 2). In these assay conditions, serotonin, the endogenous ligand for 5-HT_{1A} receptors, and the prototypical selective 5-HT_{1A} receptor agonist (+)8-OH-DPAT both increased [³⁵S]GTP γ S binding to G α_o in a concentration-dependent manner (Figure 1 and Table 2). The selective neutral 5-HT_{1A} antagonist WAY100,635

MOL # 29769

competitively reversed this effect: increasing concentration of the antagonist reversed the effects of maximally effective concentrations (1 μ M) of serotonin or (+)8-OH-DPAT (Figure 2 and Table 2).

In this hippocampal tissue homogenate preparation, spiperone and methiothepin showed inverse agonist properties, reducing basal [35 S]GTP γ S binding to $G\alpha_o$ in a concentration-dependent manner (Figure 1 and Table 2). WAY100,635 partly reversed the maximal inhibition of basal binding induced by a fixed concentration of spiperone (10 μ M) or methiothepin (1 μ M) (Figure 2 and Table 2). In comparison, when a higher concentration of NaCl (100 mM) was used, spiperone and methiothepin only inhibited [35 S]GTP γ S binding at very high concentrations (> 1 μ M; data not shown).

MOL # 29769

Discussion:

Human 5-HT_{1A} receptors expressed in recombinant cell lines have been shown to possess constitutive activity as revealed by spiperone and methiothepin inverse agonist properties (see Introduction). Similarly, constitutive activity of h5-HT_{1A} could be demonstrated when the receptor was co-expressed with GTP-binding protein G_z in Sf9 cells (Barr and Manning, 1997) and in HEK cells expressing a fusion protein combining 5-HT_{1A} to G α_{i1} (Milligan *et al.*, 2001), thus suggesting that constitutive activity is an inherent property of 5-HT_{1A} receptors. Nevertheless, multiple factors can influence detection of constitutive activity. For example, the amplitude of response to inverse agonist depends on GPCR/G-protein stoichiometry: an increase in 5-HT_{1A}/G-protein ratio increasing the amplitude of inverse agonist response (Newman-Tancredi *et al.*, 1997b). It is therefore important to assess constitutive activity of GPCR in an environment where the “natural” GPCR/G-protein ratio is expressed.

The present study is, to our knowledge, the first demonstration of constitutive activity of native rat 5-HT_{1A} receptors. Previous studies using classical [³⁵S]GTP γ S binding assay failed to detect inverse agonist properties of spiperone and methiothepin in rat brain tissue (Alper and Nelson, 1998; Newman-Tancredi *et al.*, 2003b; Odagaki and Toyoshima, 2005a; Odagaki and Toyoshima, 2005b). The study by Alper and Nelson did report that methiothepin, but not spiperone, diminished G-protein activation at high concentrations (10 μ M), but this effect was not reversed by the selective neutral antagonist WAY100,635 (Alper and Nelson, 1998), indicating that it was not related to 5-HT_{1A} receptors. In contrast, using SPA-based G α_o -selective immunocapture on [³⁵S]GTP γ S binding assay, the present study demonstrates inverse agonism at native r5-HT_{1A} receptors with both spiperone and methiothepin that was antagonized by WAY100,635. Rat hippocampal 5-HT_{1A} receptors show a strong coupling to G α_o (Mannoury la Cour *et al.*, 2006). Indeed, in the present study,

MOL # 29769

comparison of antibodies selective for various G α -proteins using SPA-based immunocapture assay showed that the most prominent response of rat hippocampal 5-HT_{1A} receptors to (+)8-OH-DPAT was activation of G α_o . The SPA-based G α_o -selective immunocapture approach used here thus permitted characterization of the inverse agonist properties of spiperone and methiothepin on 5-HT_{1A} receptors by selectively detecting the G protein showing the best coupling to 5-HT_{1A} receptors in this tissue. Under the present assay conditions, WAY100,635 had no activity of its own at concentrations up to 10 μ M, but it antagonised the effect of the agonists and inverse agonists in a competitive manner.

Calculated pK_b for this antagonism are consistent with pK_i values derived from competition binding of WAY100,635 to rat 5-HT_{1A} receptors (Newman-Tancredi *et al.*, 2005) and from pK_b previously published on similar assays (Odagaki and Toyoshima, 2005a; Odagaki and Toyoshima, 2005b). These data therefore confirm that the decreases in G α_o labelling induced by spiperone and methiothepin are indeed mediated by interaction at r5-HT_{1A} receptors.

The amplitude of the inverse agonism response observed with spiperone and methiothepin is relatively modest (10% reduction in basal labelling of G α_o , or 33% of the amplitude of agonists responses under those conditions). Two factors may contribute to the moderate inverse agonism response of these drugs on 5-HT_{1A} receptors. First of all, both drugs may be partial inverse agonists on 5-HT_{1A} receptors. Although no efficacy data are available for these 2 drugs as inverse agonists on 5-HT_{1A} receptors, this efficacy may be assessed in recombinant systems expressing these receptors alone using a [³⁵S]GTP γ S homologous displacement protocol with unlabelled GTP γ S (Audinot *et al.*, 2000; Rouleau *et al.*, 2002). Secondly, this assay being performed on tissue, several G α_o -coupled receptors may be constitutively active, thus limiting the contribution of 5-HT_{1A} to a fraction of the overall constitutive activity present in that tissue. Indeed, reversal of the response of spiperone and

MOL # 29769

methiothepin by WAY100,635 is only partial (two third of effect), suggesting that other constitutively active receptors may be involved in the effect of these 2 drugs (see below).

The demonstration that native 5-HT_{1A} receptors show constitutive activity *in vitro* may suggest that this phenomenon also occurs *in vivo*. Constitutive activity has also been demonstrated in rat brain tissues for serotonin 5-HT_{2C} receptors (De Deurwaerdere *et al.*, 2004) and H_3 histaminergic receptors (Morisset *et al.*, 2000), and certain human pathologies including metabolic diseases and some cancers are believed to be associated with abnormal levels of GPCR constitutive activity (Kenakin, 2004). It is also possible that certain neuropsychiatric diseases may be associated with GPCR showing abnormal constitutive activity and several clinically relevant drugs have been shown to have inverse agonist properties on GPCR in recombinant systems (Milligan, 2003a; Kenakin, 2004). The present study assessed the level of constitutive activity of 5-HT_{1A} receptors in hippocampal membranes prepared from brains of untreated normal animals. In view of the importance of 5-HT_{1A} receptors in neuropsychiatric disorders (Millan, 2000; Meltzer *et al.*, 2003; Newman-Tancredi *et al.*, 2005), it will be of interest to evaluate whether constitutive activity of central 5-HT_{1A} receptors may be affected by pharmacological or pathophysiological factors. A better understanding of the factors affecting 5-HT_{1A} receptors constitutive activity *in vivo* may thus help improve therapeutic approaches toward neuropsychiatric disorders.

The pharmacological behaviour of inverse agonists *in vivo* may have other physiological consequences. For example, inverse agonists may produce more prominent receptor up regulation than neutral antagonists (Adan and Kas, 2003) and inverse agonists may lead to increases in G-proteins expression levels (Kenakin, 2004). A recent electrophysiological study assessed the effect of two selective 5-HT_{1A} inverse agonists (Rec 27/0224 and Rec 27/0074) on hippocampal and dorsal raphe neurons (Corradetti *et al.*, 2005). In this physiological assay, the 2 inverse agonists fully antagonized the effect of 5-CT

MOL # 29769

applications on dorsal raphe neurons, but with a much slower time course to reach steady state than would have been expected from their binding affinities at 5-HT_{1A} receptors, or when compared to the time course to reach steady state with the neutral antagonist WAY100,635. Corradetti and colleagues suggested that this phenomenon may be explained by a slow allosteric shift of the receptor toward an inactive state (Corradetti *et al.*, 2005). Moreover, in contrast to WAY100,635, which could fully antagonize 5-CT-induced hyperpolarisation of hippocampal CA1 neurons, these 2 compounds showed only partial antagonism, suggesting that these drugs may behave differentially on neuronal populations expressing either pre- or post-synaptic 5-HT_{1A} receptors. These observations are consistent with the differential coupling of the pre- (dorsal raphe) and post-synaptic (hippocampus) 5-HT_{1A} receptors suggested by various observations (Hensler, 2002; Mannoury la Cour *et al.*, 2006) as differential response to allosteric effects of inverse agonists may be expected on differentially coupled receptor.

Three technical points should be noted concerning the data in the present study. First, buffer containing low sodium (30 mM) was used as this condition increases GPCR constitutive activity, and may therefore improve identification of inverse agonists with [³⁵S]GTPγS binding assays (de Ligt *et al.*, 2000). The role of sodium may be to allosterically stabilize the uncoupled (inactive) conformation of the receptors (de Ligt *et al.*, 2000), thus low sodium concentrations favouring the constitutively active conformation of the receptor. Allosteric modulation of GPCR ligand binding by sodium is associated with a highly conserved aspartate residue located in the second transmembrane domain, near the intracytoplasmic side of GPCR (Horstman *et al.*, 1990), a residue that may also be critical for GPCR coupling to G-proteins (Odagaki and Toyoshima, 2005a). An important issue is clearly the “physiological” concentration of NaCl affecting the levels of GPCR constitutive activity and this question remains a subject of debate (Newman-Tancredi *et al.*, 2003a).

MOL # 29769

Second, it is unlikely that the inverse agonism of methiothepin and spiperone observed here would be due to antagonism of residual endogenous serotonin in the tissue as the homogenate was preincubated for 15 minutes at 35°C in a large excess of buffer containing GTP to favour endogenous ligand dissociation, followed by several membrane washes. Moreover, WAY100,635 had no activity at concentrations up to 10 µM in these assay conditions, providing further indication that no remaining endogenous 5-HT was affecting basal [³⁵S]GTPγS binding.

Third, the inverse agonism elicited by spiperone and methiothepin was not completely reversed by WAY100,635, a residual lowering of Gα_o activation persisting even at high antagonist concentrations. This suggests that other receptor systems that couple to Gα_o may also be involved. Indeed, both spiperone and methiothepin are known to interact with other receptors at which they have been shown to be inverse agonists. For example, spiperone is acting as an inverse agonist on dopamine D₂ receptors (Roberts and Strange, 2005), and on alpha1 adrenoceptors (Rossier *et al.*, 1999), while methiothepin has inverse agonist properties on 5-HT_{1B} (Newman-Tancredi *et al.*, 2003a) and 5-HT_{1D} receptors (Audinot *et al.*, 2000). Thus, the inhibition of [³⁵S]GTPγS binding to Gα_o remaining with maximal WAY100,635 concentrations may be due to an action at other receptors. The present methodology targeting Gα_o activation provides a strategy to investigate the action of inverse agonists at other receptor subtypes.

In conclusion, these data generated by antibody capture methodology associated to SPA detection provide the first demonstration that native rat 5-HT_{1A} receptors show constitutive activation of Gα_o proteins in an hippocampal tissue environment, suggesting that rat 5-HT_{1A} receptors may be constitutively active *in vivo* at Gα_o and/or other G-protein subtypes.

MOL # 29769

Acknowledgements

The excellent technical assistance of Nathalie DANTY for performing the receptor binding assays, and Fabrice LESTIENNE for performing the western blots has been greatly appreciated.

MOL # 29769

References

Adan RA and Kas M J (2003) Inverse Agonism Gains Weight. *Trends Pharmacol Sci* **24**:315-321.

Alper RH and Nelson D L (1998) Characterization of 5-HT_{1A} Receptor-Mediated [35S]GTPγS Binding in Rat Hippocampal Membranes. *Eur J Pharmacol* **343**:303-312.

Assie MB, Cosi C and Koek W (1999) Correlation Between Low/High Affinity Ratios for 5-HT_{1A} Receptors and Intrinsic Activity. *Eur J Pharmacol* **386**:97-103.

Audinot V, Newman-Tancredi A and Millan M J (2000) Constitutive Activity at Serotonin 5-HT_{1D} Receptors: Detection by Homologous GTP[γ]S Versus [35S]-GTP[γ]S Binding Isotherms. *Neuropharmacology* **40**:57-64.

Barnes NM and Sharp T (1999) A Review of Central 5-HT Receptors and Their Function. *Neuropharmacology* **38**:1083-1152.

Barr AJ and Manning D R (1997) Agonist-Independent Activation of G_z by the 5-Hydroxytryptamine_{1A} Receptor Co-Expressed in *Spodoptera Frugiperda* Cells. Distinguishing Inverse Agonists From Neutral Antagonists. *J Biol Chem* **272**:32979-32987.

Cheng Y and Prusoff W H (1973) Relationship Between the Inhibition Constant (K_i) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I₅₀) of an Enzymatic Reaction. *Biochem Pharmacol* **22**:3099-3108.

Corradetti R, Mlinar B, Falsini C, Pugliese A M, Cilia A, Destefani C and Testa R (2005) Differential Effects of the 5-Hydroxytryptamine (5-HT)_{1A} Receptor Inverse Agonists Rec

MOL # 29769

27/0224 and Rec 27/0074 on Electrophysiological Responses to 5-HT_{1A} Receptor Activation in Rat Dorsal Raphe Nucleus and Hippocampus in Vitro. *J Pharmacol Exp Ther* **315**:109-117.

Cussac D, Newman-Tancredi A, Duqueyroi D, Pasteau V and Millan M J (2002) Differential Activation of G_{q/11} and G_{i(3)} Proteins at 5-Hydroxytryptamine(2C) Receptors Revealed by Antibody Capture Assays: Influence of Receptor Reserve and Relationship to Agonist-Directed Trafficking. *Mol Pharmacol* **62**:578-589.

Cussac D, Pasteau V and Millan M J (2004) Characterisation of G_s Activation by Dopamine D₁ Receptors Using an Antibody Capture Assay: Antagonist Properties of Clozapine. *Eur J Pharmacol* **485**:111-117.

De Deurwaerdere P, Navailles S, Berg K A, Clarke W P and Spampinato U (2004) Constitutive Activity of the Serotonin_{2C} Receptor Inhibits in Vivo Dopamine Release in the Rat Striatum and Nucleus Accumbens. *J Neurosci* **24**:3235-3241.

de Ligt RA, Kourounakis A P and IJzerman A P (2000) Inverse Agonism at G Protein-Coupled Receptors: (Patho)Physiological Relevance and Implications for Drug Discovery. *Br J Pharmacol* **130**:1-12.

Hensler JG (2002) Differential Regulation of 5-HT_{1A} Receptor-G Protein Interactions in Brain Following Chronic Antidepressant Administration. *Neuropsychopharmacology* **26**:565-573.

Horstman DA, Brandon S, Wilson A L, Guyer C A, Cragoe E J, Jr. and Limbird L E (1990) An Aspartate Conserved Among G-Protein Receptors Confers Allosteric Regulation of Alpha₂-Adrenergic Receptors by Sodium. *J Biol Chem* **265**:21590-21595.

MOL # 29769

- Kenakin T (2004) Efficacy As a Vector: the Relative Prevalence and Paucity of Inverse Agonism. *Mol Pharmacol* **65**:2-11.
- Mannoury la Cour C, El Mestikawy S, Hanoun N, Hamon M and Lanfumey L (2006) Regional Differences in the Coupling of 5-HT_{1A} Receptors to G Proteins in the Rat Brain. *Mol Pharmacol* **70**:1013-1021.
- Martel JC, Ormiere A M, Assie M B, Cussac D and Newman-Tancredi A (2005) Spiperone and Methiothepin Act As Inverse Agonists on Native Rat Hippocampal 5-HT_{1A} Receptors Coupled to G α _O Protein. *Soc Neurosci Abstr* **31**:373.
- McLoughlin DJ and Strange P G (2000) Mechanisms of Agonism and Inverse Agonism at Serotonin 5-HT_{1A} Receptors. *J Neurochem* **74**:347-357.
- Meltzer HY, Li Z, Kaneda Y and Ichikawa J (2003) Serotonin Receptors: Their Key Role in Drugs to Treat Schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* **27**:1159-1172.
- Millan MJ (2000) Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)_{1A} Receptors. *J Pharmacol Exp Ther* **295**:853-861.
- Milligan G (2003a) Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: a Current Perspective. *Mol Pharmacol* **64**:1271-1276.
- Milligan G (2003b) Principles: Extending the Utility of [³⁵S]GTP Gamma S Binding Assays. *Trends Pharmacol Sci* **24**:87-90.
- Milligan G, Kellett E, Dacquet C, Dubreuil V, Jacoby E, Millan M J, Lavielle G and Spedding M (2001) S 14506: Novel Receptor Coupling at 5-HT_{1A} Receptors. *Neuropharmacology* **40**:334-344.

MOL # 29769

Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin C R, Schwartz J C and Arrang J M (2000) High Constitutive Activity of Native H3 Receptors Regulates Histamine Neurons in Brain. *Nature* **408**:860-864.

Newman-Tancredi A, Assie M B, Leduc N, Ormiere A M, Danty N and Cosi C (2005) Novel Antipsychotics Activate Recombinant Human and Native Rat Serotonin 5-HT1A Receptors: Affinity, Efficacy and Potential Implications for Treatment of Schizophrenia. *Int J Neuropsychopharmacol* **8**:341-356.

Newman-Tancredi A, Conte C, Chaput C, Spedding M and Millan M J (1997a) Inhibition of the Constitutive Activity of Human 5-HT1A Receptors by the Inverse Agonist, Spiperone but Not the Neutral Antagonist, WAY 100,635. *Br J Pharmacol* **120**:737-739.

Newman-Tancredi A, Conte C, Chaput C, Verrielle L and Millan M J (1997b) Agonist and Inverse Agonist Efficacy at Human Recombinant Serotonin 5-HT1A Receptors As a Function of Receptor:G-Protein Stoichiometry. *Neuropharmacology* **36**:451-459.

Newman-Tancredi A, Cussac D, Marini L and Millan M J (2002) Antibody Capture Assay Reveals Bell-Shaped Concentration-Response Isotherms for H5-HT(1A) Receptor-Mediated Galpha(I3) Activation: Conformational Selection by High-Efficacy Agonists, and Relationship to Trafficking of Receptor Signaling. *Mol Pharmacol* **62**:590-601.

Newman-Tancredi A, Cussac D, Marini L, Touzard M and Millan M J (2003a) H5-HT(1B) Receptor-Mediated Constitutive Galphai3-Protein Activation in Stably Transfected Chinese Hamster Ovary Cells: an Antibody Capture Assay Reveals Protean Efficacy of 5-HT. *Br J Pharmacol* **138**:1077-1084.

Newman-Tancredi A, Rivet J M, Cussac D, Touzard M, Chaput C, Marini L and Millan M J (2003b) Comparison of Hippocampal G Protein Activation by 5-HT(1A) Receptor Agonists

MOL # 29769

and the Atypical Antipsychotics Clozapine and S16924. *Naunyn Schmiedebergs Arch Pharmacol* **368**:188-199.

Newman-Tancredi A (2003) Differential Ligand Efficacy at H5-HT1A Receptor-Coupled G-Protein Subtypes: a Commentary. *International Congress Series* **1249**:101-117.

Odagaki Y and Fuxe K (1995) Pharmacological Characterization of the 5-Hydroxytryptamine-1A Receptor-Mediated Activation of High-Affinity GTP Hydrolysis in Rat Hippocampal Membranes. *J Pharmacol Exp Ther* **274**:337-344.

Odagaki Y and Toyoshima R (2005a) 5-HT1A Receptor-Mediated G Protein Activation Assessed by [³⁵S]GTPγS Binding in Rat Cerebral Cortex. *Eur J Pharmacol* **521**:49-58.

Odagaki Y and Toyoshima R (2005b) Detailed Pharmacological Characterization of 5-HT1A-Receptor-Mediated [³⁵S]GTP γ S Binding in Rat Hippocampal Membranes. *J Pharmacol Sci* **98**:66-76.

Roberts DJ and Strange P G (2005) Mechanisms of Inverse Agonist Action at D2 Dopamine Receptors. *Br J Pharmacol* **145**:34-42.

Rossier O, Abuin L, Fanelli F, Leonardi A and Cotecchia S (1999) Inverse Agonism and Neutral Antagonism at Alpha(1a)- and Alpha(1b)-Adrenergic Receptor Subtypes. *Mol Pharmacol* **56**:858-866.

Rouleau A, Ligneau X, Tardivel-Lacombe J, Morisset S, Gbahou F, Schwartz J C and Arrang J M (2002) Histamine H3-Receptor-Mediated [³⁵S]GTP γ[S] Binding: Evidence for Constitutive Activity of the Recombinant and Native Rat and Human H3 Receptors. *Br J Pharmacol* **135**:383-392.

MOL # 29769

Seifert R and Wenzel-Seifert K (2002) Constitutive Activity of G-Protein-Coupled Receptors: Cause of Disease and Common Property of Wild-Type Receptors. *Naunyn Schmiedebergs Arch Pharmacol* **366**:381-416.

Stanton JA and Beer M S (1997) Characterisation of a Cloned Human 5-HT_{1A} Receptor Cell Line Using [³⁵S]GTP Gamma S Binding. *Eur J Pharmacol* **320**:267-275.

Wu S and Liu B (2005) Application of Scintillation Proximity Assay in Drug Discovery. *BioDrugs* **19**:383-392.

MOL # 29769

Legends for Figures:

Figure 1 : A) Validation of the specificity of anti-G α_o antibodies by western blot (see materials and methods for details).

B) Concentration-response curves of [35 S]GTP γ S binding to G α_o in rat hippocampal membranes. Data are the average of 3-5 independent determinations, and are expressed as percent changes from basal (defined as 100%). Serotonin and (+)-8-OH-DPAT increased [35 S]GTP γ S binding to G α_o whereas both spiperone and methiothepin reduced basal binding in a concentration dependent manner (see Table 2 for derived constants).

Figure 2 : Reversal by increasing concentrations of WAY100,635 of the effect of a fixed concentration of drugs on [35 S]GTP γ S binding to G α_o in rat hippocampal membranes. Data are the average of 3-5 independent determinations, and are expressed as percent changes from basal (defined as 100%). (see Table 2 for derived constants).

MOL # 29769

Tables:

Table 1 : Characterisation of G α protein subtypes coupled to 5-HT_{1A} receptors in rat



hippocampal membrane preparations. The levels of [³⁵S]GTP γ S binding elicited by 10 μ M (+)8-OH-DPAT was compared to basal binding (defined as 100%) using an SPA-based immuno-capture assay with a series of characterized G α -subtype specific antibodies (see materials and methods for details). Results are expressed as raw DPM, and as percent changes from corresponding basal [³⁵S]GTP γ S binding and are the mean \pm SEM of 4 independent determinations.

Antibodies	Basal	10 μ M (+)8-OH-DPAT	
	DPM (N)		% chg. from BASAL
Anti-G $\alpha_{q/11}$	517 \pm 20 (4)	614 \pm 23 (4)	19 \pm 1
Anti-G $\alpha_{s/olf}$	526 \pm 33 (4)	586 \pm 18 (4)	13 \pm 10
Anti-G α_{i1}	4302 \pm 457 (4)	4027 \pm 374 (4)	-6 \pm 1
Anti-G α_{i3}	822 \pm 41 (4)	1193 \pm 6 (4)	46 \pm 7
Anti-Gα_o	6541 \pm 615 (4)	11148 \pm 829 (4)	71 \pm 6

MOL # 29769

Table 2: Constants derived from [³H]8-OH-DPAT binding and [³⁵S]GTPγS binding to Gα_o in rat hippocampal membranes. Results are mean ± SEM of 3-5 independent determinations.

Drug	Binding [³ H]8-OH-DPAT	[³⁵ S]GTPγS binding to Gα _o			+ WAY100,635
	pKi (N)	pEC ₅₀	pIC ₅₀	E _{max} (as % Basal) (N)	pK _B (N)
5-HT	8.73 ± 0.04 (3)	7.91 ± 0.06	---	129.3 ± 5.8 (5)	9.57 ± 0.16 (5)
(+)-8-OHDPAT	9.15 ± 0.11 (3)	7.87 ± 0.12	---	126.7 ± 2.3 (4)	9.52 ± 0.07 (3)
Spiperone	7.03 ± 0.11 (3)	---	7.37 ± 0.21	91.6 ± 2.1 (4)	9.52 ± 0.20 (4)
Methiothepin	7.60 ± 0.01 (3)	---	7.98 ± 0.25	91.0 ± 0.5 (4)	8.87 ± 0.44 (3)
WAY100,635	9.33 ± 0.03 (3)	---	---	---	---

A**G α_{i1}** **G α_{i2}** **G α_{i3}** **G α_o** **G α_s** **G $\alpha_{q/11}$** **40 kDa -****B****[³⁵S]GTP γ S
binding to G α_o** 

[³⁵S]GTP_γS binding to Gα_o

